S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Options Trading Plan–Perfect For Beginners (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
New AI Stock Payouts (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
NASDAQ:AERI

Aerie Pharmaceuticals (AERI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$15.25
$15.25
50-Day Range
$15.18
$15.25
52-Week Range
$4.81
$15.37
Volume
600 shs
Average Volume
974,748 shs
Market Capitalization
$753.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AERI stock logo

About Aerie Pharmaceuticals (NASDAQ:AERI) Stock

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.


AERI Stock News Headlines

Aerie Promo Codes
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk
I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.
Angina Pectoris Drugs Global Market Report 2023
Ocular Hypertension Treatment Global Market Report 2023
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
I-Mab Announces the Appointment of Raj Kannan as CEO
I-Mab Names Raj Kannan CEO - Quick Facts
Ophthalmic Drugs Global Market Report 2023
See More Headlines
Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AERI Company Calendar

Last Earnings
11/04/2021
Today
9/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AERI
Employees
376
Year Founded
N/A

Profitability

Net Income
$-74,810,000.00
Pretax Margin
-16.47%

Debt

Sales & Book Value

Annual Sales
$194.13 million
Book Value
($3.32) per share

Miscellaneous

Free Float
47,223,000
Market Cap
$753.61 million
Optionable
Optionable
Beta
-0.06
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 58)
    CEO, Principal Financial Officer & Director
    Comp: $753.49k
  • Dr. Casey C. Kopczynski Ph.D. (Age 61)
    Co-Founder, Chief Innovation Officer & Head of Research and External Innovation
    Comp: $685.06k
  • Mr. John W. LaRocca Esq. (Age 57)
    Gen. Counsel & Sec.
    Comp: $676.62k
  • Mr. Peter F. Lang (Age 50)
    Chief Financial Officer
  • Dr. Michelle Senchyna Ph.D.
    Head of Clinical Devel. & Operations
  • Mr. Jeffrey M. Calabrese CPA (Age 55)
    VP of Fin. & Principal Accounting Officer
  • Ms. Carolyn McAuliffe
    Sr. Director of Communications
  • Ms. Wanda Francies
    Head of HR
  • Mr. Marvin J. Garrett (Age 71)
    Head of Regulatory Affairs & Quality Assurance
  • Mr. Craig R. Skenes
    Head of Bus. Devel.













AERI Stock - Frequently Asked Questions

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) issued its quarterly earnings results on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. The business earned $29.31 million during the quarter, compared to analysts' expectations of $29.13 million. During the same period in the prior year, the firm posted ($0.65) EPS.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $15.25.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $753.61 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

The company employs 376 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787.

This page (NASDAQ:AERI) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -